The National Cancer Center will be developing new medicine for cancer hand in hand with multinational pharmaceutical companies.

The center’s new medicine development team concluded a deal with Sanofi-Aventis Korea, agreeing to transfer substances and jointly develop potential substances for new treatment.

The center’s team will be conducting pre-clinical examinations on potential substances for the new medicine, while Sanofi-Aventis Korea will be testing the effectiveness of the treatment.

The National Cancer Center says amid limited resources for developing new medicine, it decided to work together with a multinational firm to raise its global competitiveness.

The team aims to transfer the technology of four potential substances that have completed preliminary clinical trials for new medicine over the next five years by investing 240-billion won.